^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Jivadco (trastuzumab duocarmazine) (HER2-targeted antibody-drug conjugate, DNA replication inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.
Published date:
05/16/2018
Excerpt:
Efficacy has also been demonstrated in heavily pretreated patients with HER2-low metastatic breast cancer, including hormone-receptor positive (N = 32) and triple-negative breast cancer (N = 17)….SYD985 shows promising efficacy in heavily pretreated patients with breast cancer, in both HER2-positive and HER2-low tumors with or without hormone receptor expression.
DOI:
10.1200/JCO.2018.36.15_suppl.1014
Trial ID:
